Oral Wegovy Approval Is The Critical 2026 Lifeline Novo Nordisk Needs

Group 1 - The article discusses the competitive landscape between Novo Nordisk and Eli Lilly as they enter a new phase in their long-standing rivalry, particularly focusing on the GLP-1 oral medication market [1] - The analysis emphasizes the importance of a fundamentals-first approach in investment decisions, despite the influence of market sentiment and algorithm-driven trading [1] Group 2 - The author has a background in Economics and has been managing investments since 1999, gaining insights across various market cycles [1] - The article does not provide any specific investment recommendations or positions in the companies mentioned, indicating an objective analysis [2][3]